Telephone
61.3.9389.1911
Address
655 Elizabeth Street Melbourne, Victoria (VIC) 3000
Description
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 228.65 - 314.28
Trade Value (12mth)
US$36,074,723.00
1 week
1.85%
1 month
10.4%
YTD
-6.7%
1 year
-12.93%
All time high
342.75
EPS 3 yr Growth
0.500%
EBITDA Margin
28.60%
Operating Cashflow
$2,601m
Free Cash Flow Return
11.20%
ROIC
9.60%
Interest Coverage
8.50
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
485m
HALO Sector
Healthcare
Next Company Report Date
13-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.65
Date | Announcements |
---|---|
31 October 22 |
CSL Notice of Research & Development Investor Briefing
×
CSL Notice of Research & Development Investor Briefing |
31 August 22 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
31 August 22 |
Change of Director's Interest Notice (x8)
×
Change of Director's Interest Notice (x8) |
30 April 19 |
Seqirus Presentation at 2019 Macquarie Equities Conference
×
Seqirus Presentation at 2019 Macquarie Equities Conference |
29 May 23 |
Shareholder Briefing
×
Shareholder Briefing |
29 May 20 |
ASA Presentation
×
ASA Presentation |
29 December 21 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
28 March 23 |
CSL European Investor Site Tour Presentations
×
CSL European Investor Site Tour Presentations |
28 March 23 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
27 September 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
26 August 22 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
26 August 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
25 October 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
25 August 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
25 August 23 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
25 August 23 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
25 August 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
24 February 23 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
24 February 23 |
Change of Director's Interest Notice x 8
×
Change of Director's Interest Notice x 8 |
24 February 22 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
24 February 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
24 August 18 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
23 October 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
23 August 06 |
Preliminary Final Report/Full Year Accounts/Presentation
×
Preliminary Final Report/Full Year Accounts/Presentation |
22 July 22 |
Becoming a substantial holder
×
Becoming a substantial holder |
22 December 21 |
Proposal to Appoint Deloitte as External Auditor
×
Proposal to Appoint Deloitte as External Auditor |
22 August 12 |
Full Year Results, Appendix 4E and Analysts Presentation
×
Full Year Results, Appendix 4E and Analysts Presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.